Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.41 USD
+0.03 (7.58%)
Updated May 3, 2024 03:52 PM ET
2-Buy of 5 2
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PBLA 0.41 +0.03(7.58%)
Will PBLA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PBLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PBLA
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
PBLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
Other News for PBLA
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
Panbela Therapeutics announces delay of expected data from pancreatic cancer treatment trial
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Panbela Therapeutics Updates ASPIRE Trial Timeline